Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/111824
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBousman, C.en
dc.contributor.authorForbes, M.en
dc.contributor.authorJayaram, M.en
dc.contributor.authorEyre, H.en
dc.contributor.authorReynolds, C.en
dc.contributor.authorBerk, M.en
dc.contributor.authorHopwood, M.en
dc.contributor.authorNg, C.en
dc.date.issued2017en
dc.identifier.citationBMC Psychiatry, 2017; 17(1):60-1-60-7en
dc.identifier.issn1471-244Xen
dc.identifier.issn1471-244Xen
dc.identifier.urihttp://hdl.handle.net/2440/111824-
dc.descriptionPublished online: 08 February 2017en
dc.description.abstractAbout half of people who take antidepressants do not respond and many experience adverse effects. These detrimental outcomes are in part a result of the impact of an individual's genetic profile on pharmacokinetics and pharmcodynamics. If known and made available to clinicians, this could improve decision-making and antidepressant therapy outcomes. This has spurred the development of numerous pharmacogenetic-based decision support tools. In this article, we provide an overview of pharmacogenetic decision support tools, with particular focus on tools relevant to antidepressants. We briefly describe the evolution and current state of antidepressant pharmacogenetic decision support tools in clinical practice, followed by the evidence-base for their use. Finally, we present a series of considerations for clinicians contemplating use of these tools and discuss the future of antidepressant pharmacogenetic decision support tools.en
dc.description.statementofresponsibilityChad A. Bousman, Malcolm Forbes, Mahesh Jayaram, Harris Eyre, Charles F. Reynolds, Michael Berk, Malcolm Hopwood and Chee Ngen
dc.language.isoenen
dc.publisherBioMed Centralen
dc.rights© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.subjectPrecision Medicine; Pharmacogenetics; Major depressive disorder; Psychiatry; Decision Supporten
dc.titleAntidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic toolsen
dc.typeJournal articleen
dc.identifier.rmid0030085542en
dc.identifier.doi10.1186/s12888-017-1230-5en
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1059660en
dc.identifier.pubid341046-
pubs.library.collectionPsychiatry publicationsen
pubs.library.teamDS03en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
Appears in Collections:Psychiatry publications

Files in This Item:
File Description SizeFormat 
hdl_111824.pdfPublished version757.9 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.